This poster describes the ARROW study, a 5-year open-label randomized trial in 1200 HIV-infected children from 3 sites in Uganda (800 children) and one in Zimbabwe (400 children), addressing 2 strategic management questions: whether children on antiretroviral therapy (ART) can be safely monitored by clinical assessment, without routine laboratory monitoring of toxicity or CD4 count; and whether induction with 4 drugs followed by maintenance on 3 drugs improves outcome in patients with high viral loads, compared to treatment with 3 drugs throughout. Several other questions are addressed by sub-studies. The baseline characteristics of the participants are described; they were younger than most African cohorts of children starting ART, severely immunocompromised, markedly wasted and stunted, and switching to tablets at an early age.
Nahirya-Ntege, P.; Bakeera-Kitaka, S.; Bwakura-Dangarembizi, M.F.; Musiime, V.; Thomason, M.; Munderi, P.; Kekitiinwa, A.; Nathoo, K.; Mugyenyi, P.; Cook, A.; Musoke, P.; Maganda, A.; Gibb, D.M. ARROW study design and baseline characteristics: AntiRetroviral Research fOr Watoto. Presented at AIDS 2008 – XVII International AIDS Conference, Mexico City, Mexico, 3-8 August 2008. (2008)
ARROW study design and baseline characteristics: AntiRetroviral Research fOr Watoto.